Express Mail No. EV 641 736 666 US

| INFORMATION | Attorney Docket | RICE-050 | |
|--|--|----------------------|--|
| DISCLOSURE STATEMENT | First Named Inventor | MACKAY, CHARLES REAY | |
| | Application Number | 10/584,480 | |
| | Confirmation No. | 3065 | |
| | Filing Date | Not yet assigned | |
| Address to: | Group Art Unit | Not yet assigned | |
| Mail Stop Box PCT Commissioner for Patents | Examiner Name | Not yet assigned | |
| P.O. Box 1450 Alexandria, VA 22313-1450 | Title: "TRANSGENIC NON-HUMAN MAMMAL COMPRISING A POLYNUCLEOTIDE ENCODIN HUMAN OR HUMANIZED C5AR" | | |

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RICE-050 may be charged thereon.

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

PTO/SB/08a (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Complete if Known

Substitute for form 1448A/PTO
INFORMATION DISCLOSURE

Application Number 10/584,480

INFORMATION DISCLOSURE Filing Date Not yet assigned STATEMENT BY APPLICANT First Named Inventor MACKAY, CHARLES REAY Art Unit Not yet assigned Examiner Name Not yet assigned (Use as many sheets as necessary) Sheet Attomey Docket Number RICE-050 of 1

| | | | | U.S. PATENT D | OCUMENTS | |
|-----------------------|--------------|--|---|--------------------------------|--|---|
| Examiner Initials' | Cite No.1 | Document Number Number-Kind Code ² (if known | , | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | us- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | us. | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | us- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------|---|--------------------------------|--|---|----|
| Examiner Initials' | Cite No.1 | Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁶ (# known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | τ• |
| /M.W./ | | WO 98/24893 | 06/11/1998 | Abgenix, Inc. | | |
| /M.W. | | WO 94/20142 | 09/15/;1994 | Center for Blood Research, Inc. | | |
| /M.W. | | WO 95/00164 | 01/05/1995 | The Scripps Research Institute | | |

| miner nature /Michael Wilson/ (09/18/2008) | Date Considered | 09/18/2008 |
|--|--------------------|------------|
|--|--------------------|------------|

"EXAMINER: Initial if interence considered, whether or not obtain is in conformance with NPEP 090. Draw fine through claifs int not in conformance and not considered, include copy of this form with need communication to applicant." Against an unique california estignation under optionals," See Krinds Codes of USPTO Patent Documents at www.usglo gov or NPEP 0910.4. "Earler Office that issued the document, by the two-leter code (VIPEO Standard ST.3)." For Japanese patent documents, but including the standard ST.3)." For Japanese patent document, but include the standard ST.3," For Japanese patent document, but include the standard ST.3," For Japanese patent document, but include the standard ST.3, "For Japanese patent document, but included the standard ST.3," For Japanese patent document, but included the standard ST.3, "For Japanese patent document, but included the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japanese patent document, but in the standard ST.3," In the standard ST.3, "For Japa

This collection of information is required by 37 CFR 197 and 1.88. The information is required to obtain or retain a benefit by the public which is to fine (and by the USPTO log process) an application. Confidentiality is operated by 58 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form andor suggestions for reducing this burdow, should be sent to the Christ Information C.U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Abexandris, V.A. 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND 170. Commissioner for Patents, P.O. 80x 1450, Alexandris, V.A. 22313-1450.

PTO/SB/08b (09-06) Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 10/584,480 Application Number INFORMATION DISCLOSURE Filing Date Not yet assigned MACKAY, CHARLES REAY First Named Inventor STATEMENT BY APPLICANT Art Unit Not yet assigned Examiner Name Not yet assigned (Use as many sheets as necessary) RICE-050 Sheet 2 of Attomey Docket Number

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|--------------|---|----|--|--|
| Examiner Initials* | Cite No.1 | include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T² | | |
| /M.W.; | | Gerard, N. P. et al. Human chemotaxis receptor genes cluster at 19q13.3-13.4. characterization of the human C5a receptor gene. Biochemistry (1993), 32: 1243-1250. | | | |
| /M.W./ | 100 | Höpken, U.E. et al. The C5a chemoattractant receptor mediates mucosal defence to infection, Nature (1996), 383: 86-89. | | | |
| /M.W./ | | Heller et al. Selection of a CSa receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. The Journal of Immunology (1999) 163: 985-994. | | | |
| /M.W./ | | Köhl, J. et al. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Molecular Immunology (2001) 38: 175-187. | | | |
| | | | | | |
| | | | | | |
| | | * | | | |
| | | | | | |

| Examiner Signature | /Michael Wilson/ (09/18/2008) | Date Considered | 09/18/2008 |
|-----------------------|-------------------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.